Episode Details
Back to Episodes
Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
Published 10 months ago
Description
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne.